Skip to main content
. 2015 Jun 24;35(25):9526–9538. doi: 10.1523/JNEUROSCI.3686-14.2015

Figure 6.

Figure 6.

Treatment with Aβ25–35 peptide increases HC activity of MCs present in brain slices. HC activity of MCs present in coronal brain slices of WT and Panx 1 knock-out (Panx1−/−) mice was evaluated using the Etd uptake assay. A, Four left panels, Representative images of Etd uptake (red) in MCs from WT brain slices identified by immunostaining with anti-CD117 (green) under control conditions (Ctrl) and after 2 h of treatment with 10 μm25–35 peptide, 20 min of pretreatment with HC blockers [200 μm La3+ and/or 1 mm probenecid (Pbc), and pretreated with 10 μm masitinib. Right, Graph showing the time course of the Aβ25–35 peptide (black columns) and the effect of 1 h Aβ1–42 (gray columns) on Etd uptake (normalized) in brain CD117-positive cells. B, Quantification of normalized Etd fluorescence intensity with respect to control condition in CD117-positive cells after 2 h of treatment with Aβ25–35 peptide (n = 5) and 20 min of pretreatment with: 200 μm La3+, 200 μm Gap26 mimetic peptide, 1 mm Pbc, 200 μm 10Panx1 mimetic peptide, and 10 μm masitinib (*p < 0.05, ***p < 0.0005 ANOVA Tukey's test, n.s., values are mean ± SEM; n = 3).

HHS Vulnerability Disclosure